Kamada Ltd Quick Ratio (KMDA) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kamada Ltd   (NASDAQ: KMDA)

Kamada Ltd 's Quick Ratio

KMDA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Kamada Ltd 's Cash & cash equivalent grew by 4.82 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Kamada Ltd 's Quick Ratio to 1.07, Quick Ratio remained below Kamada Ltd average.

Within Major Pharmaceutical Preparations industry 181 other companies have achieved higher Quick Ratio than Kamada Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 879.

Explain Quick Ratio?
How much Cash & cash equivalents KMDA´s has?
What are KMDA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KMDA Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 43.02 % 114.52 % 78.64 % 96.94 % -44.75 %
Y / Y Cash & cash equivalent Change -3.78 % -0.01 % 16.69 % 58.21 % 40.97 %
Quick Ratio MRQ 1.07 0.99 0.9 1.04 1.59
KMDA's Total Ranking # 879 # # # #
Seq. Current Liabilities Change -3.15 % -0.17 % -0.21 % 48.24 % 45.27 %
Seq. Cash & cash equivalent Change 4.82 % 9.11 % -13.46 % -2.79 % 8.94 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 182
Healthcare Sector # 335
Overall Market # 879


Quick Ratio Statistics
High Average Low
2.81 1.27 0.34
(Dec 31 2020)   (Dec 31 2021)




Financial Statements
Kamada Ltd 's Current Liabilities $ 71 Millions Visit KMDA's Balance sheet
Kamada Ltd 's Cash & cash equivalent $ 75 Millions Visit KMDA's Balance sheet
Source of KMDA's Sales Visit KMDA's Sales by Geography


Cumulative Kamada Ltd 's Quick Ratio

KMDA's Quick Ratio for the trailling 12 Months

KMDA Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 79.51 % 33.32 % -6.59 % -35.79 % -49.56 %
Y / Y Cash & cash equivalent TTM Growth 13.53 % 25.94 % 37.41 % 58.92 % 96.2 %
Quick Ratio TTM 1 1.09 1.27 1.43 1.58
Total Ranking TTM # 3080 # # # #
Seq. Current Liabilities TTM Growth 7.91 % 16.95 % 16.28 % 22.32 % -19.86 %
Seq. Cash & cash equivalent TTM Growth -1.01 % -0 % 3.33 % 10.99 % 9.81 %

Quick ratio ranking by company, industry and sector >> Back to KMDA Financial Strength Comparisons >> Go to Compare KMDA Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q4 2025 to $70.64 millions, cumulative Quick Ratio decreased to 1 below the Kamada Ltd average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 382 other companies have achieved higher Quick Ratio than Kamada Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 3080.

Explain Quick Ratio?
How much Cash & cash equivalents KMDA´s has?
What are KMDA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 383
Healthcare Sector # 798
Within the Market # 3080


trailing twelve months Quick Ratio Statistics
High Average Low
2.81 1.15 0.34
(Dec 31 2020)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Mirum Pharmaceuticals Inc   2.89 $ 732.452  Millions$ 253.075  Millions
Nurix Therapeutics Inc   2.86 $ 246.960  Millions$ 86.471  Millions
Proqr Therapeutics N v   2.85 $ 103.503  Millions$ 36.334  Millions
Cellectar Biosciences Inc   2.84 $ 13.196  Millions$ 4.650  Millions
Verastem Inc   2.84 $ 204.990  Millions$ 72.268  Millions
Pds Biotechnology Corp  2.83 $ 26.712  Millions$ 9.447  Millions
Tvardi Therapeutics Inc   2.82 $ 30.811  Millions$ 10.926  Millions
Nasus Pharma Ltd   2.82 $ 4.286  Millions$ 1.520  Millions
Can fite Biopharma Ltd   2.82 $ 8.540  Millions$ 3.029  Millions
Connect Biopharma Holdings Limited  2.82 $ 38.348  Millions$ 13.613  Millions
Oculis Holding Ag  2.79 $ 102.481  Millions$ 36.747  Millions
Fibrobiologics Inc   2.78 $ 4.894  Millions$ 1.759  Millions
Biohaven Ltd   2.75 $ 319.137  Millions$ 115.934  Millions
Foghorn Therapeutics Inc   2.66 $ 158.894  Millions$ 59.738  Millions
Sol gel Technologies Ltd   2.63 $ 23.909  Millions$ 9.082  Millions
Bio Green Med Solution Inc   2.63 $ 3.505  Millions$ 1.332  Millions
Precigen Inc   2.62 $ 97.858  Millions$ 37.306  Millions
Avenue Therapeutics Inc   2.60 $ 2.855  Millions$ 1.099  Millions
Acadia Pharmaceuticals Inc   2.57 $ 819.686  Millions$ 318.692  Millions
Arbutus Biopharma Corp  2.56 $ 18.095  Millions$ 7.081  Millions
Genelux Corporation  2.52 $ 14.595  Millions$ 5.798  Millions
Xilio Therapeutics Inc   2.50 $ 137.531  Millions$ 54.930  Millions
Beone Medicines Ltd   2.49 $ 4,547.530  Millions$ 1,828.830  Millions
Processa Pharmaceuticals Inc   2.48 $ 5.537  Millions$ 2.236  Millions
Nextcure Inc   2.46 $ 25.982  Millions$ 10.566  Millions
Scienture Holdings Inc   2.44 $ 6.662  Millions$ 2.735  Millions
Hyperion Defi inc   2.39 $ 6.443  Millions$ 2.701  Millions
Nuvectis Pharma inc   2.38 $ 31.634  Millions$ 13.296  Millions
Seres Therapeutics Inc   2.37 $ 45.766  Millions$ 19.322  Millions
Satellos Bioscience Inc   2.35 $ 9.804  Millions$ 4.177  Millions

Date modified: 2026-09-18T14:10:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.